The Pharma Data

DECEMBER 13, 2020

.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. He received his B.S.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 59

Gene Editing Genomics Genome Engineer 59

The Pharma Data

NOVEMBER 3, 2020

LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is headquartered in Lexington, Mass. For more information, please visit www.logicbio.com.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genomics 40

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. There is an incredible unmet need in some diseases that can only be addressed through cell and gene therapies.”. However, she said the company wants to strengthen its position in gene editing.

Gene Therapy 52

Gene Therapy Gene Gene Editing Business Development 52

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Financial details were not disclosed.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40